

23/6/01
JC903 U.S. PRO
09/981876
10/19/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ruben et al.

Application Serial No.: TBA

Art Unit: TBA

Filed: concurrently herewith

Examiner: TBA

For: **Secreted Protein HRGDF73**
(as amended herein)

Atty. Docket No.: PZ001G67AP1D1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-AN listed on the attached form PTO/SB/08. A copy of each of references AF and AG is enclosed.

Copies of references AA-AE and AH-AN were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 09/148,545 filed September 4, 1998, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/148,545 for copies of references AA-AE and AH-AN.

The relevance of References AF (WO 00/53755) and AG (WO 01/40466) can be found throughout the specification, particularly with references to PRO619.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of

the listed documents should they be applied as references against the claims of the subject application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Date: OCTOBER 19, 2001


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723 (phone)

JMM/LT/lcc

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Ruben, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	PZ001G67APID1

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	5,536,637		Jacobs	07-16-1996	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³ (known)	Number ⁴	Kind Code ⁵ (if known)			
	AB	WO	90/14432		Genetics Institute, Inc.	11-29-1990	
	AC	WO	96/17925		Immunex Corporation	06-13-1996	
	AD	WO	97/04097		Genetics Institute, Inc.	02-06-1997	
	AE	WO	97/07198		Genetics Institute, Inc.	02-27-1997	
	AF	WO	00/53755	✓	Genentech, Inc.	09-14-2000	
	AG	WO	01/40466	✓	Genentech, Inc.	06-07-2001	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	AH	HILLIER et al., Genbank Accession No. W52490 (10-11-1996)
	AI	GUELLAEN, Genbank Accession No. AA065307 (12-31-1996)
	AJ	GUELLAEN, Genbank Accession No. AA065306 (12-31-1996)
	AK	HILLIER et al., Genbank Accession No. AA151194 (05-14-1997)
	AL	HILLIER et al., Genbank Accession No. AA234924 (08-06-1997)
	AM	OCCHIODORO et al., "Human alpha-L-fucosidase: complete coding sequence from cDNA clones", Biochem. and Biophys. Res. Comm., 164(1):439-445 (1989)
	AN	JACOBS et al., "Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes", J. of Cell. Biochem. Suppl. 0 (21A), page 19, abstr. No. C1-207 (1995)

Examiner Signature	Date Considered
--------------------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

JC903 U.S. PTO
09/981876